WO1994013822A2 - Methods for stable transformation of wheat - Google Patents
Methods for stable transformation of wheat Download PDFInfo
- Publication number
- WO1994013822A2 WO1994013822A2 PCT/US1993/012085 US9312085W WO9413822A2 WO 1994013822 A2 WO1994013822 A2 WO 1994013822A2 US 9312085 W US9312085 W US 9312085W WO 9413822 A2 WO9413822 A2 WO 9413822A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- callus
- tissue
- type
- wheat
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8206—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated
- C12N15/8207—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0025—Culture media for plant cell or plant tissue culture
Definitions
- the present invention relates to the transformation and regeneration of fertile transformed plants, particularly wheat.
- Wheat is one of the most important cereal crops in the world. While it is currently being grown in a wide range of environments, the most prominent production of wheat occurs in the USA, China, Australia, Canada, India and Europe.
- the present invention is drawn to a method for the stable transformation of wheat with nucleic acid sequences of interest and the regeneration of fertile transgenic wheat plants. Particularly it concerns a method for producing stably transformed fertile wheat plants, said method comprising:
- Type II callus tissue obtained from wheat tissue is bombarded with particles coated with a DNA sequence of interest which sequence comprises a dhfr gene, the bombarded tissue is grown on medium containing methotrexate to selct transformed tissue, and fertile transformed plants are regenerated from said transformed tissue.
- the wheat tissues are transformed using high velocity microprojectile bombardment and stably transformed plants are regenerated. The method produces stably transformed fertile wheat plants capable of producing progeny which are stably transformed and which express the foreign gene of interest.
- a rapid, highly efficient method for the stable transformation of wheat cells and the regeneration of transgenic wheat plants involves stably transforming a wheat cell and regenerating wheat plants from transformed wheat cells.
- fertile transgenic wheat plants can be grown to maturity with a high frequency.
- the fertile transformed plants are capable of producing transformed progeny that express the foreign gene(s).
- the method involves subjecting wheat tissues to high velocity projectile bombardment using nucleic acid or particularly, genes of interest.
- Wheat tissues that are capable of transformation according to the methods of the invention include calli, cell suspension cultures, anthers, microspores, embryos, inflorescences, and the like.
- Cell suspension cultures can be derived from calli of embryos, leaf tissues, young inflorescences, anthers, etc.
- Callus can be originated from any tissues of wheat plants including Triticum aestivum and Triticum durum.
- tissue utilized in initiating callus is immature tissue such as immature embryos, immature inflorescences, and the basal portion of young leaves.
- callus can be originated from anthers, microspores, mature embryos and in principle any other tissue of wheat capable of forming callus and or secondary embryos.
- An especially useful tissue for producing regenerable callus is the scutellum of immature wheat embryos.
- the term callus refers to regenerable callus, further divisible into Type I callus and Type II callus as defined in corn (See, for example. Ozias-Atkins et al.
- Callus useful in the method of the invention includes Type 1 and Type II callus ( Figure 1) preferably derived from immature embryos, inflorescence, anthers, or leaves, which is induced from explants cultured on a medium containing sucrose or other carbohydrate source.
- callus which has been derived from immature embryos on a medium containing maltose, hereafter referred to as Type M callus or Type II callus derived on a maltose-containing medium.
- callus tissue is selected from Type M callus, Type I callus and Type II callus.
- sucrose has been used almost exclusively as the energy source, usually at levels of 2-3%.
- a basal medium comprising micronutrients, macronutrients, a carbon source, iron, vitamins, and plant growth regulators.
- Plant growth regulators are known in the art and include auxins, cytokinins and gibberellins. Such regulators may depend on the step in the process and the particular wheat genotype utilized.
- Type M callus ( Figure 2) can be obtained directly from culturing immature embryos on maltose-containing medium. The maltose-induced embryo callus is friable, granular with visible somatic embryos, and relatively slow growing. Maltose may be added into the tissue culture medium at a level of about 1 to about 30%, preferably about 11 to about 18%. The exposure time of embryos to maltose may range from about 3 to about 42 days, preferably about 7 to about 28 days.
- Plant growth regulators useful in the invention include those with auxin-like functions such as IAA, NAA, 2,4-D, 2,4,5-T dicamba, p-chlorophenoxyacetic acid and the like. Such regulators may be added to the maltose-containing medium at a level of about 0.5 mg/1 to about 100 mg/1, preferably about 1 mg/1 to about 40 mg/1, and most preferably about 2 to about 10 mg/1.
- 2,4-D is the preferred plant growth regulator for inducing Type M callus from wheat immature embryos cultured on a maltose-containing medium.
- the Type M callus may be used as a target tissue for transformation. It is also used directly in generating cell suspension cultures or in generating Type II callus.
- Type M callus or Type M-derived Type II callus By utilizing Type M callus or Type M-derived Type II callus, a regenerable cell suspension culture is obtained within 3 months from embryo culture. This is much shorter than the conventional method (at least 6 to 8 months) where sucrose is used as the major carbohydrate source in the medium.
- the Type M-derived Type II callus and the Type II-derived cell suspension cultures are also highly regenerable. Up to 400 plants can be regenerated per gram (fresh weight) of such Type II callus.
- Type M callus and Type M-derived Type II callus of the invention yield fertile plants and progeny. In fact, up to about 89% of the plants regenerated from 9-month-old Type M and Type M-derived Type II callus produce seeds.
- Type M and Type 11 callus, and their derived cell suspension cultures are suitable for transformation. They yield a large number of transformants and fertile plants and progeny.
- First Type II callus is friable. That is, the callus is characterized as small cell aggregates.
- the Type II callus of the invention is also highly competent for the establishment of regenerable cell suspension cultures, yields a large number of transformants, is highly regenerable and yields fertile plants and progeny. In general Type II callus culture is more amenable in bombardment protocols and for selection of transformed tissue.
- the tissue to be transformed is bombarded with a high particle bombardment device.
- Particle bombardment offers a rapid method for transformation. See, generally, Finer et al. (1992) Plant Cell Reports 11:323-328; Christou P (1990) Physiologia Plantarum 79:210-212; Wang et al. (1988) Plant Molecular Biology 11:433-439; Daniell et al. (1991) Plant Cell Reports 9:615-619; Klein et al. (1988) Proc. Natl. Acad. Sci. USA 85:4305-4309; Klein et al- (1987) Nature 327:70-73; Gordon-Kamm et al.
- Such disclosed particle gun is capable of introducing particles carrying genetic material into a wide variety of cells.
- the gun comprises:
- the gun has a rapid firing cycle as well as a consistent force and accuracy of the shots fired.
- the gun provides a controlled, reproducible, adjustable and safe propulsion source.
- An additional benefit of the gun disclosed in WO 93/07256 is that the gun requires less DNA for bombardment than other devices known in the art.
- other devices for plant cell bombardment as for example the helium powered acceleration system (Sanford et al., Technique-J. Meth. in Cell und Molec. Biol. 3:3-16, 1991) are equally preferred.
- the tissue is shot at least one time. However, multiple shots of the tissue may be performed to enhance transformation frequency. Thus subjecting the tissue to multiple shots of DNA coated particles constitutes a preferred embodiment of the invention. About two shots per transformation have been demonstrated to yield best results.
- the particles used as DNA carriers in the bombardments were generally about 0.5 to about 2.0 micron in diameter, more specifically about 1.0 micron.
- the particles are coated with at least about 0.5 ⁇ g to about 2.0 ⁇ g, preferrably with about 1 ⁇ g DNA per wheight of the particles.
- Particles useful in the invention are commercially available. For example, gold particles from BioRad Company can be utilized.
- the particle gun of WO 93/07256 allows for the control of the pressure.
- a pressure in the range of about 500 psi to about 2500 psi, preferably about 1900 psi may be utilized.
- the tissue may be subjected to a plasmolysis treatment before bombardment, after bombardment, or preferably both before and after bombardment.
- Plasmolysis treatment may be performed by diluting cells in a liquid medium with added osmoticum or by transferring cells to semisolid medium containing plasmolyzing agent.
- the osmoticum can be any sugar such as sorbitol, mannitol, sucrose and the like.
- the growth medium may additionally comprise auxin.
- the cells After bombardment the cells are grown for several days in the dark on growth medium with auxin. Typically the cells are grown for about 5 to about 10 weeks, more specifically about 1 to about 7 weeks, before being subjected to selection pressure.
- a number of selective agents and resistance genes are known in the art. (See, for example, Hauptmann et al. (1988) Plant Physiol. 86: 602-606; Dekeyser et al. (1988) Plant Physiol. 90: 217-223; Eichholtz . et al. (1987) Somatic Cell and Molecular Genetics 13: 67-76; Meijer et al. (1991) Plant Molecular Biology 16: 807-820; and Dekeyser et al.
- Inhibitors such as amino-glycoside antibiotics which interfere with the translation machinery of prokaryotic and eukaryotic cells, may be utilized. Such inhibitors include kanamycin, G418, hygromycin, etc. Such inhibitors can be inactivated by phosphorylation reactions mediated by the products of either the Tn 5 neomycin phosphotransferase II (npt-II) gene or the hygromycin B resistance gene from E. coli. (See, for example, Herrera-Estrella et al. (1983) EMBO J 2: 987-995; Waldron et al. (1985) Plant Mol Biol 5: 103-108; and the references cited therein.)
- methotrexate binds to the catalytic site of the dihydrofolate reductase enzyme, resulting in a deficiency of thymidylate and subsequent cell death.
- chimeric constructs containing a bacterial or mouse dhfr gene can confer resistance to low levels of methotrexate in transformed tobacco, tumip, petunia and rice plants.
- the transformed and selected tissue After growth on selection medium the transformed and selected tissue is allowed to grow. After several weeks, from about 4 to about 30 weeks, the tissue is transferred to medium for regeneration.
- transformed wheat plants One of the major obstacles to the production of transformed wheat plants has been methods for regeneration of plants from transformed tissues.
- transformed callus is grown on either a hormone-free medium containing sucrose, on a medium containing a cytokinin, or on a medium containing auxin and gibberellin. The callus cultures are transferred to the light. Plant development is continued on a hormone-free medium or medium with auxin. After development of roots and shoots, plantlets are transferred to soil and grown to maturity.
- DNA is extracted from the tissue (callus and plant) and probed to confirm transformation.
- Methods are available in the art for the isolation of DNA from callus and tissues as well as for confirming the presence of DNA of interest. Such methods to confirm include PCR analysis as well as Southern hybridization. See, Southern, EM (1975) J Mol Biol 98:503 and Mullis, KB (1987) Meth in Enzymology 155:335.
- any gene of interest can be used in the methods of the invention.
- a wheat plant can be engineered to express disease and insect resistance genes, genes conferring nutritional value, genes to confer male and/or female sterility, antifungal, antibacterial or antiviral genes, and the like.
- the method can be used to transfer any nucleic acid to control gene expression.
- the DNA to be transferred could encode antisense RNA.
- Type II callus is used as the target tissue.
- the callus tissue is shot twice with DNA coated 1.0 micron gold particles.
- Bombardment parameters include 1.0 micron particles; 2 shots per target; 0.6 ⁇ g DNA per shot; 1900 psi; plasmolysis treatment both pre- and post-bombardment.
- the bombarded tissue is subjected to selection on methotrexate in the range of about 0.1 to about 20 ⁇ g/ml methotrexate, more specifically about 0.5 to about 5 ⁇ g/ml methotrexate for about four months.
- the tissue is transferred to MS medium containing about 0.1 to about 1.0 mg/1 2,4-D in the dark.
- the tissue After the tissue has formed embryogenic structures, it is transferred to MS medium containing about 0.5 to about 1 mg/1 NAA, and about 0.5 to about 10 mg/1 GA and placed in the light for about two weeks. After shoot induction the tissues are transferred to MS medium without hormones or half-strength MS containing about 0.1 to about 1 mg/1 NAA for root induction.
- transformed callus lines are obtained with a high efficiency compared to other published reports. In fact up to 50% efficiency can be seen as confirmed by PCR and/or Southern analysis. Transformation experiments routinely yield stable transformants at a frequency as high as about 50% based on the number of transformants obtained per number of targets shot. Furthermore, by utilizing methotrexate selection, regenerated plants test positive for transformation.
- the method can be used to transform embryos, mature or immature.
- spikes from greenhouse grown wheat plants are collected about 10 to about 16, generally about 12 days after anthesis. Kernels are separated from the spikes and surface sterilized. Embryos are then excised and plated on growth medium. 0 to 10 days post excision, DNA is delivered to the embryo using a particle bombardment device. After DNA delivery the embryo or developing callus can be maintained without selection pressure and then the tissue can be regenerated in the presence or absence of selection. Alternatively, plants are regenerated from the bombarded tissue without selection and regenerated plants tested for the presence of the delivered DNA. Improved embryogenic cultures of wheat can be obtained by using previously regenerated material as a source of starting material.
- Such improved cultures are referred to as "recycled lines" since they are “cycled” through the tissue culture process more than once.
- the starting material for these improved cultures may be either immature embryos obtained directly from regenerated plants, or the starting material may be seeds from regenerated plants grown as as source of immature embryos.
- the embryogenic cultures so derived have improved initiation frequency and fertility of regenerants compared to traditional, non-recycled lines. These improvements significantly increase the ease and efficiency with which transgenic wheat and its progeny may be obtained.
- Figure 1 shows wheat Type II callus induced from immature embryos.
- Figure 2 shows wheat Type M callus induced from immature embryos.
- Type M callus globular, somatic embryos developing on the scutellum of certain explants. These calli were removed and placed either on MS medium containing 1.0 to 5.0 mg/1 2,4-D and 2-3% sucrose or on a medium containing a reduced level (5%) of maltose before being placed on the sucrose medium. The material was then subcultured every week to fresh MS medium containing 3% sucrose. II. Genotvpic response of wheat in Type M callus induction.
- Type M callus formation 10 mg/1 2,4-D plus 13.7% maltose (10MS13.7M) to induce Type M callus formation. After three weeks culture in the dark at 27°C, the induction frequency (%) of Type M callus, Type I callus, as well as non-morphogenic structures from the immature embryos of the tested genotypes were scored.
- Type M callus induction frequency 52%
- Type M callus induction frequency 44%
- the cells for bombardment were given a plasmolysis treatment before and after bombardment. Packed cell volume was measured and cells were diluted in IMS liquid medium with added osmoticum: 0.4M sorbitol for suspension cells and 0.6M sorbitol for callus cells. Cells were diluted such that the final packed cell volume per target was 1/20 ml for a fine suspension and 1/10 ml for callus. Diluted cells were placed in a 250 ml flask containing a stir bar and stirred for a minimum of 30 minutes, up to a few hours. To plate the cells, 2 ml were withdrawn from the flask and pipetted into the top of a vacuum flask onto which a Whatman 2.5 cm GFA filter was placed.
- the filters were placed on 60x15 mm petri plates containing 5 ml of solid post-bombardment plasmolysis medium, which is IMS containing 0.2M sorbitol for suspension cells, or 0.4M sorbitol for callus cells. Two filters were plated on each dish.
- pSOG30 is a ⁇ -glucuronidase (Gus) expression vector derived from plasmid pBI121 , purchased from Clontech Laboratories, Palo Alto, California.
- Intron 6 of the maize Adhl gene was amplified by PCR from plasmid pB428, described in Bennetzen et al, Proc. Natl. Acad. Sc , USA 81: 4125-4128 (1987) and ligated into the BamHl site of pBI121 , which is between the CaMV 35S promoter and the Gus gene.
- MCMV chlorotic mottle virus
- pSOG35 is a dihydrofolate reductase (dhfr) expression vector. This construct was derived by fusing the 35S promoter, Adhl intron 6, and MCMV leader described above to the dhfr gene from plasmid pHCO, described in Bourouis and Jarry, EMBO J.
- the final gene fusion contains the structure: 35S promoter- Adh 1 intron 6-MCMV leader-dhfr-Nos terminator, all in the pUC19 vector backbone.
- pTG48 comprises the Gus gene under control of the anther specific ant43D promoter and a dhfr gene in a pUC19 backbone. It is the result from the combination of 4 different DNA fragments. Fragment 1 was obtained from pSOG35 after restriction cutting with Hindlll and EcoRI. The EcoRI end of the isolated fragment containing the dhfr gene was adapted to a Sail restriction end.
- Fragment 2 consisted of the anther specific ant43D promoter isolated from plasmid pCIB 3178 after restriction cutting with Hindlll and Xbal. Plasmid pCIB 3178 is described in detail in the European patent application numer 93810455.1 the relevant parts of which are incorporated herein by reference and was deposited under accession no. NRRL B-18978. Fragment 3 was obtained from plasmid pSOG30 after restriction cutting with Xbal and EcoRI and contained the Gus gene, and fragment 4 corresponded to the commercially available vector pUC19 cut with Sail and EcoRI. VI. Particle Preparation
- Gold particles (1.0 micron; from Bio-Rad) were washed by aliquoting into a microfuge tube, adding - ⁇ 1 ml 100% ethanol, vortexing, spinning down, removing the supernatant, and repeating twice with sterile water. After the final wash, as much water was removed as possible and polylysine solution (0.02% polylysine + 15mM ammonium acetate) was added to completely immerse the particles. The particles were vortexed, spun, and the supernatant removed. The particles were allowed to dry overnight in a laminar flow hood or for 30 minutes under a gentle nitrogen stream.
- the petri plate containing the cell filters was inverted onto the platform on top of the stage, and centered over the particle flight opening.
- the clear lid was placed over the top of the platform.
- a microprojectile was placed onto the breech pin and the breech closed.
- the "arm” button was pushed to fill the reservoir with the appropriate amount of helium gas (usually 1800-1900 psi).
- the vacuum on the chamber was pulled to ⁇ 27 mm. After the vacuum was turned off, and the "arm” and “fire” buttons were pushed. The “arm” button was then pushed to the "off position.
- Each filter was usually shot twice.
- 0.5MS maintenance medium which is an aqueous solution of MS salts, vitamins, iron, 3% sucrose, 0.7% agar, 0.5 mg/liter 2,4-D. Tissue was subcultured onto this medium biweekly until embryogenic structures appeared or tissue seemed suitable for regeneration.
- Tissue was transferred to MS medium containing either 3 mg/liter BAP or 1 mg/liter NAA + 5 mg/liter GA, and plates were moved to the light. After 2-4 weeks, tissue was transferred to MS medium without hormones. Shoots that appeared were placed in containers with either MS medium without hormones or MS medium with 0.5 mg liter NAA. When sufficient root and shoot growth had occurred, plantlets were transferred to soil and placed in a phytotron.
- Type II callus derived from Type M callus was obtained from immature embryos of the spring wheat genotype UC703 using the methods described above.
- the resulting callus line, called UC703-0612 was friable, embryogenic, and serially propagated in vitro.
- a microprojectile device was used to deliver DNA to the Type II callus.
- pSOG30 and pSOG35 were co-precipitated onto micrometer sized gold particles and introduced into plant cells.
- Plant SJ3-2A-1 was grown to maturity in a greenhouse and was pollinated with wild- type pollen from UC703 plants. Two seeds developed, from which two immature embryos were excised and germinated. One rescued embryo produced one T ⁇ plant (known as RE1), while the second rescued embryo was placed on callus induction medium and subsequently produced ten T ⁇ plants, two of which are known as RE2 and RE3. Leaf samples from RE1 were assayed for Gus enzyme activity and were positive. PCR analysis for presence of 35S promoter sequences was done on RE1, RE2, and RE3 and all three plants were positive. Southern analysis was done to probe for the presence of the Gus and gene in these three progeny plants, and all three were positive for the gene.
- T ⁇ plants RE1, RE2, and RE3 (also known as RE2B) were pollinated with wild type UC703 pollen to produce T2 plants. Many seeds developed on each plant and immature embryos were rescued and germinated in vitro. Fluorimetric Gus assays were done and transformants were identified from a segregating population.
- XII Transformation of wheat by microprojectile bombardment of immature embryos and isolation of transformants without the use of a selectable marker or selection agent.
- Immature embryos of genotype UC703, 0.75-1.5 mm in length were excised and plated onto MS medium containing 5 mg/liter 2,4-D and 3% sucrose, 30 embryos per plate.
- Two plasmids were co-precipitated onto micrometer size gold particles and introduced into plant cells by the DuPont Biolistics device using standard techniques as published in the operations manual.
- One plasmid, pCIB3089 contains the cauliflower mosaic virus 35S promoter (Nature 313:810-812, 1985) fused to the cDNA of the maize anthocyanin regulatory gene B-peru (Plant. Mol. Biol.
- pCIB4436 contains the CaMV 35S promoter (Nature 313:810-812, 1985) fused to the cDNA of the maize anthocyanin regulatory gene Cl (EMBO Journal 9:2517-2522, 1990; Genes and Development 5:298-309, 1991; and Genes and Development 6:864-875, 1992), with intron #9 of the maize PEP-carboxylase gene (Plant Mol. Biol.
- T ⁇ generation In order to analyze the T ⁇ generation, fifty-seven immature embryos from this PCR positive plant were excised, germinated, and analyzed. Of these, forty-one T ⁇ plants were PCR positive for both the B-peru and Cl genes. Twenty-two seed-derived T ⁇ plants were also found to be PCR positive for these genes. Southern analysis was done on the parent plant and three PCR positive Tj progeny. All were positive for B-peru and negative for Cl by this analysis. The T2 generation was grown in the greenhouse for seed production.
- XIII Transformation of wheat by microprojectile bombardment of immature embryos using a high sucrose plasmolysis step prior to gene delivery.
- Immature embryos (0.75-1.0 mm length) of the wheat genotype UC703 were plated on Murashige and Skoog medium (Physiologia Plantarum 15: 473-497, 1962) containing 3 mg/liter 2,4-D and 3% sucrose. Twenty embryos were placed on each plate of medium. Three days later the immature embryos were transferred to the same medium but containing an additional 15% sucrose in order to plasmolyze the tissue prior to gene delivery.
- Plasmids pActl-D (The Plant Cell 2:163-171, 1990) and pSOG35 were precipitated onto micrometer size gold particles using standard procedures. Each plate of embryos were shot twice with the DuPont Biolistics helium device using a burst pressure of 900 psi. A total of four target plates were bombarded using the standard 80 mesh screen and four plates were shot without the screen in place. Approximately 4 hours after bombardment the embryos were transferred back to Murashige and Skoog medium containing 3% sucrose.
- XIV Transformation of wheat by microprojectile bombardment of immature embryos using a high maltose plasmolysis step prior to gene delivery.
- Immature embryos (0.75-1.0 mm length) of gentotype UC703 were plated on Murashige and Skoog medium containing 3 mg/1 2,4-D and 3% sucrose. After approximately 4 hours the embryos were plated with the embryo axis side down onto plates containing Murashige and Skoog medium with 15% maltose, 3% sucrose and 3 mg/1 2,4-D overlayed with a filter paper supported slab of agarose containing the same components. The embryos were allowed to plasmolyze for 2-3 hours before bombardment. DNA of pActl-D (The Plant Cell 2:163-171, 1990) and pSOG35 was precipitated onto micrometer size gold particles using standard procedures.
- the responding tissue was placed on Murashige and Skoog medium with 3 mg/1 2,4-D and 3% sucrose with 0.2 mg/1 methotrexate for a 3 week period.
- the tissue was then placed on a regeneration medium comprised of Murashige and Skoog medium with 1 mg/1 zeatin riboside and 1 mg/1 methotrexate.
- regenerating plantlets were placed in sterile containers called "GA7s" with half-strength Murashige and Skoog salts, 2% sucrose, 1 mg/1 NAA and either 4 or 8 mg/1 methotrexate.
- XV Development of improved embryogenic cultures of wheat using previously regenerated material as a culture source.
- Immature embryos 1-2 mm in size, were removed from caryopses under a dissecting microscope and cultured on a Murashige and Skoog medium with either 5 or 10 mg/1 2,4-D and 13.7 g /l maltose, or on a Murashige and Skoog medium with 2 mg/1 2,4-D and 3% sucrose.
- This newly induced friable callus now recycled, was transferred to a Murashige and Skoog medium with 1 mg/1 2,4-D and 3% sucrose for maintenance or bombardment experiments.
- the above plant regeneration and callus induction process were then repeated to produce future generations of friable callus.
- embryos from wild-type plants were collected and cultured on the same maltose medium.
- the induction frequency of a friable and embryogenic callus from the embryos was recorded and are shown below.
- a Type II cell culture (UC703-0612), which was produced from an embryo grown on a maltose-containing medium, was thawed out from cryopreservation and placed on a maintenance medium (Murashige and Skoog medium + 1 mg/1 2,4-D + 3% sucrose). The callus was then placed on a medium containing Murashige and Skoog basal salts and 3 mg/1 6-BAP for plant regeneration. Seeds were harvested from the regenerated plants arid then germinated in soil. For embryo culture, wheat spikes were collected from the seed-derived plants, sterilized with 10% Clorox solution for 10 min, and rinsed several times with sterile water.
- Immature embryos 1-2 mm in size, were removed from caryopses under a dissecting microscope and cultured on a Murashige and Skoog medium with 2 or 10 mg/1 2,4-D and 13.7 g /l maltose, or on a MS medium with 2 mg/1 2,4-D and 3% sucrose.
- the induced friable callus was transferred to a MS medium with 1 mg/1 2,4-D and 3% sucrose for maintenance or bombardment experiments.
- embryos from wild-type plants were collected and cultured on the same maltose medium.
- the induction frequencies of friable and embryogenic callus from the embryos were recorded and are shown below.
- XVI Transformation of wheat using a recycled embryogenic culture.
- a recycled, embryogenic callus line labelled 0612RC was developed as described in the above example.
- Callus was prepared for bombarding by stirring and plasmolyzing for 2-3 hours in liquid Murashige and Skoog medium containing lmg/1 2,4-D, 3% sucrose and 0.6M sorbitol in a ratio of 1 part cells to 16 parts medium.
- Each target was prepared by using a vacuum filter appartus to affix 3ml of the cell mixture to glass fiber filters which were then placed onto solid Murashige and Skoog medium with 1 mg/1 2,4-D, 3% sucrose and 0.4M sorbitol.
- DNA from plasmid pTG48 (ant43/Gus/35Sdhfr) was precipitated onto micrometer size gold particles using 0.1M CaCl2 and 0.1M Na ⁇ PO
- Each target was shot twice with the microprojectile device described in WO 93/07256 using a gas pressure of 1900 psi.
- the filters and cells were removed from the sorbitol medium and placed on Murashige and Skoog medium with 1 mg/1 2,4-D and 3% sucrose approximately 24 hours later and allowed to grow for 17 days before placing on the same medium but with lmg/1 methotrexate included.
- the selection level was increased to 2 mg/1 methotrexate 17 days later.
- Plantlets were transferred to sterile containers called "GA7s" containing 1/2-strength Murashige and Skoog salts, 2% sucrose and 0.5 mg/1 NAA approximately 20 weeks after bombardment. Plants were transferred to the greenhouse for propagation. Five plants were analyzed by Southerns and the presence of the dhfr gene was confirmed.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Botany (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Cereal-Derived Products (AREA)
- Noodles (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
Abstract
Description
Claims
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU57493/94A AU688297B2 (en) | 1992-12-16 | 1993-12-13 | Methods for stable transformation of wheat |
| EP94903608A EP0674715B2 (en) | 1992-12-16 | 1993-12-13 | Methods for stable transformation of wheat |
| DK94903608T DK0674715T4 (en) | 1992-12-16 | 1993-12-13 | Process for stable wheat transformation |
| DE69325389T DE69325389T3 (en) | 1992-12-16 | 1993-12-13 | Process for the stable transformation of wheat |
| CA002151127A CA2151127C (en) | 1992-12-16 | 1993-12-13 | Methods for stable transformation of wheat |
| GR990402132T GR3031054T3 (en) | 1992-12-16 | 1999-08-23 | Methods for stable transformation of wheat. |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99239192A | 1992-12-16 | 1992-12-16 | |
| US07/992,391 | 1992-12-16 | ||
| US08/147,261 US5610042A (en) | 1991-10-07 | 1993-11-01 | Methods for stable transformation of wheat |
| US08/147,261 | 1993-11-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1994013822A2 true WO1994013822A2 (en) | 1994-06-23 |
| WO1994013822A3 WO1994013822A3 (en) | 1994-09-15 |
Family
ID=26844765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1993/012085 Ceased WO1994013822A2 (en) | 1992-12-16 | 1993-12-13 | Methods for stable transformation of wheat |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US5610042A (en) |
| EP (1) | EP0674715B2 (en) |
| AT (1) | ATE181364T1 (en) |
| AU (1) | AU688297B2 (en) |
| CA (1) | CA2151127C (en) |
| DE (1) | DE69325389T3 (en) |
| DK (1) | DK0674715T4 (en) |
| ES (1) | ES2134925T5 (en) |
| GR (1) | GR3031054T3 (en) |
| WO (1) | WO1994013822A2 (en) |
Cited By (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0709462A3 (en) * | 1994-10-26 | 1997-01-02 | Monsanto Co | Fast and efficient regeneration of transgenic plants |
| WO1998004723A1 (en) * | 1996-07-26 | 1998-02-05 | Regents Of The University Of Minnesota | Fertile transgenic oat plants |
| WO1998048613A1 (en) * | 1997-04-29 | 1998-11-05 | The Regents Of The University Of California | Compositions and methods for plant transformation and regeneration |
| WO1999015003A1 (en) * | 1997-09-24 | 1999-04-01 | The Regents Of The University Of California | Methods and compositions for transformation of cereals using cultured shoot meristematic tissue |
| US6002068A (en) * | 1996-12-19 | 1999-12-14 | Novartis Finance Corporation | Methods for conferring insect resistance to a monocot using a perioxidase coding sequence |
| US6642437B1 (en) | 1997-09-30 | 2003-11-04 | The Regents Of The University Of California | Production of proteins in plant seeds |
| WO2005123926A1 (en) | 2004-06-18 | 2005-12-29 | Thomas Schmulling | Method for modifying plant morphology, biochemistry and physiology comprising expression of cytokinin oxydase in the seeds |
| US7026528B2 (en) | 1996-06-21 | 2006-04-11 | Monsanto Technology Llc | Methods for the production of stably-transformed, fertile wheat employing agrobacterium-mediated transformation and compositions derived therefrom |
| US7102056B1 (en) | 1997-04-29 | 2006-09-05 | The Regents Of The University Of California | Compositions and methods for plant transformation and regeneration |
| US7262055B2 (en) | 1998-08-25 | 2007-08-28 | Gendaq Limited | Regulated gene expression in plants |
| US7285416B2 (en) | 2000-01-24 | 2007-10-23 | Gendaq Limited | Regulated gene expression in plants |
| US7429691B2 (en) | 2002-09-03 | 2008-09-30 | The Regents Of The University Of California | Methods and compositions for transformation and regeneration of maize |
| EP2078455A1 (en) | 2001-03-06 | 2009-07-15 | The Dow Chemical Company | Plant cell having animal-type sugar chain adding function |
| US7667099B2 (en) | 2002-06-20 | 2010-02-23 | Board Of Trustees Of Michigan State University | Plastid division and related genes and proteins, and methods of use |
| US7781648B2 (en) | 2005-05-18 | 2010-08-24 | Board Of Trustees Of Michigan State University | Resistance to soybean aphid in early maturing soybean germplasm |
| US7834244B2 (en) | 2004-12-21 | 2010-11-16 | Huazhong Agricultural University | Transcription factor gene OsNACx from rice and use thereof for improving plant tolerance to drought and salt |
| EP2258856A1 (en) | 1998-02-20 | 2010-12-08 | Syngenta Limited | Hybrid seed production |
| EP2290084A2 (en) | 2003-06-30 | 2011-03-02 | Commonwealth Scientific and Industrial Research Organization | Wheat with altered branching enzyme activity and starch and starch containing products derived therefrom |
| EP2390333A1 (en) | 2002-07-23 | 2011-11-30 | Novozymes Biopharma DK A/S | Polypeptides comprising a modified human serum albumin secretion pre-sequence with improved secretion yield |
| WO2013005211A2 (en) | 2011-07-05 | 2013-01-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Boron complexing plant materials and uses thereof cross-reference to related applications |
| US8362318B2 (en) | 2008-12-18 | 2013-01-29 | Board Of Trustees Of Michigan State University | Enzyme directed oil biosynthesis in microalgae |
| EP2666867A1 (en) | 2006-07-12 | 2013-11-27 | The Board Of Trustees Operating Michigan State University | DNA encoding ring zinc-finger protein and the use of the DNA in vectors and bacteria and in plants |
| US8674176B2 (en) | 2003-05-29 | 2014-03-18 | Ingo H. Heilmann | ADS genes for reducing saturated fatty acid levels in seed oils |
| US9133475B2 (en) | 2008-11-26 | 2015-09-15 | Board Of Trustees Of Michigan State University | Aphid resistant soybean plants |
| US9187761B2 (en) | 2006-09-25 | 2015-11-17 | Thomas Schmulling | Transcriptional repressors of cytokinin signaling and their use |
| WO2016039961A1 (en) | 2014-09-11 | 2016-03-17 | Marrone Bio Innovations, Inc | Chromobacterium subtsugae genome |
| US9307708B2 (en) | 2014-03-07 | 2016-04-12 | Pioneer Hi-Bred International Inc | Systems for extracting monocot embryos |
| US9328335B2 (en) | 2009-12-30 | 2016-05-03 | Board Of Trustees Of Michigan State University | Method to produce acetyldiacylglycerols (ac-TAGs) by expression of an acetyltransferase gene isolated from Euonymus alatus (burning bush) |
| US10253329B2 (en) | 2013-01-04 | 2019-04-09 | Board Of Trustees Of Michigan State University | Sources of aphid resistance in soybean plants |
| US10392629B2 (en) | 2014-01-17 | 2019-08-27 | Board Of Trustees Of Michigan State University | Increased caloric and nutritional content of plant biomass |
Families Citing this family (233)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6605712B1 (en) * | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| US5610042A (en) * | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
| US6872871B2 (en) * | 1998-02-02 | 2005-03-29 | Odyssey Thera Inc. | Mapping molecular interactions in plants with protein fragments complementation assays |
| MX257801B (en) | 1997-06-02 | 2008-06-10 | Syngenta Participations Ag | Plant transformation methods |
| US6060315A (en) * | 1997-12-01 | 2000-05-09 | Lockheed Martin Energy Research Corporation | Method for facilitating the introduction of material into cells |
| US6153811A (en) * | 1997-12-22 | 2000-11-28 | Dekalb Genetics Corporation | Method for reduction of transgene copy number |
| US5973227A (en) * | 1998-05-06 | 1999-10-26 | University Of Saskatchewan | Flax transformation |
| US7897843B2 (en) | 1999-03-23 | 2011-03-01 | Mendel Biotechnology, Inc. | Transcriptional regulation of plant biomass and abiotic stress tolerance |
| US20050086718A1 (en) | 1999-03-23 | 2005-04-21 | Mendel Biotechnology, Inc. | Plant transcriptional regulators of abiotic stress |
| CN1423520B (en) | 1999-11-10 | 2011-05-04 | 安·斯雷德 | Compositions and methods for regulating plant cell division |
| AU780463B2 (en) | 1999-11-17 | 2005-03-24 | Mendel Biotechnology, Inc. | Environmental stress tolerance genes |
| EP1950306A1 (en) | 1999-11-17 | 2008-07-30 | Mendel Biotechnology, Inc. | Environmental stress tolerance genes |
| US6812028B1 (en) * | 1999-12-10 | 2004-11-02 | University Of Guelph | Embryogenesis and plant regeneration from microspores |
| US6580019B1 (en) | 2000-03-09 | 2003-06-17 | Dekalb Genetics Corporation | Non-reciprocal recombination-mediated transgene deletion in transgenic plants |
| US6750379B2 (en) | 2000-03-09 | 2004-06-15 | Dekalb Genetics Corporation | Homologous recombination-mediated transgene alterations in plants |
| US6806399B1 (en) * | 2000-04-19 | 2004-10-19 | Carmel-Haifa University Economic Corporation Ltd. | Pollen-mediated method for transformation of maize, tomato or melon |
| US6995016B2 (en) | 2000-08-17 | 2006-02-07 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food | Process for inducing direct somatic embryogenesis in immature scutella cells of pooideae, and rapidly regenerating fertile plants |
| WO2002015675A1 (en) | 2000-08-22 | 2002-02-28 | Mendel Biotechnology, Inc. | Genes for modifying plant traits iv |
| FR2815969B1 (en) | 2000-10-30 | 2004-12-10 | Aventis Cropscience Sa | TOLERANT PLANTS WITH HERBICIDES BY METABOLIC BYPASS |
| EP1465988A4 (en) | 2001-03-19 | 2005-08-03 | Cargill Inc | Myo-inositol oxygenases |
| JP2004532213A (en) * | 2001-04-06 | 2004-10-21 | ザ ユニヴァーシティ オヴ シカゴ | Chemotherapy induction of EGR-1 promoter activity |
| US20040242523A1 (en) * | 2003-03-06 | 2004-12-02 | Ana-Farber Cancer Institue And The Univiersity Of Chicago | Chemo-inducible cancer gene therapy |
| US8034791B2 (en) | 2001-04-06 | 2011-10-11 | The University Of Chicago | Activation of Egr-1 promoter by DNA damaging chemotherapeutics |
| JP4338402B2 (en) | 2001-05-22 | 2009-10-07 | ユニバーシティ オブ シカゴ | N4 virus single-stranded DNA-dependent RNA polymerase |
| US20050287647A9 (en) | 2001-05-30 | 2005-12-29 | Carl Perez | Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes |
| ATE536100T1 (en) | 2001-10-26 | 2011-12-15 | Baylor College Medicine | COMPOSITION FOR ALTERING BONE PROPERTIES IN A SUBJECT |
| CA2469310C (en) | 2001-12-11 | 2013-01-29 | Advisys, Inc. | Plasmid mediated supplementation for treating chronically ill subjects |
| WO2003064621A2 (en) * | 2002-02-01 | 2003-08-07 | Ambion, Inc. | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| WO2003064626A2 (en) | 2002-02-01 | 2003-08-07 | Sequitur, Inc. | Double-stranded oligonucleotides |
| US20060009409A1 (en) * | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| BRPI0311324B1 (en) | 2002-05-22 | 2020-01-28 | Monsanto Technology Llc | polynucleotide, vector, polypeptide with desasturase activity, methods for plant production and corn oil containing omega-3 fatty acids, to increase the nutritional value of an edible product, food or feed manufacture, as well as edible composition |
| US20040248094A1 (en) * | 2002-06-12 | 2004-12-09 | Ford Lance P. | Methods and compositions relating to labeled RNA molecules that reduce gene expression |
| US6916474B2 (en) | 2002-07-15 | 2005-07-12 | Board Of Regents, The University Of Texas System | Antibodies with increased affinities for anthrax antigens |
| US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
| KR101170653B1 (en) | 2002-08-12 | 2012-08-03 | 제네렉스, 인코포레이티드 | Methods and compositions concerning poxviruses and cancer |
| BR0314389A (en) | 2002-09-18 | 2005-07-12 | Mendel Biotechnology Inc | Plant polynucleotides and polypeptides |
| EP2933334B1 (en) * | 2003-02-18 | 2019-09-18 | Baylor College of Medicine | Induced activation in dendritic cells |
| TW200424214A (en) * | 2003-04-21 | 2004-11-16 | Advisys Inc | Plasmid mediated GHRH supplementation for renal failures |
| EP1788861B1 (en) | 2004-08-24 | 2017-04-12 | Monsanto Technology, LLC | Adenylate translocator protein gene non-coding regulatory elements for use in plants |
| BRPI0517462A (en) | 2004-10-21 | 2008-10-07 | Charles L Niblett | methods and materials for conferring resistance to plant pests and pathogens |
| AU2005333165B2 (en) | 2004-11-12 | 2012-07-19 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| AR053269A1 (en) | 2005-05-16 | 2007-04-25 | Monsanto Technology Llc | CORN PLANTS AND SEEDS WITH IMPROVEMENT OF ASPARAGIN AND PROTEIN |
| KR20080052570A (en) | 2005-07-29 | 2008-06-11 | 타게티드 그로스 인코퍼레이티드 | Dominant Negative Mutation of RPRP Protein Protection of Active Cyclin-CDV Complex Inhibition by Wild-type RPP |
| US9180149B2 (en) * | 2005-09-07 | 2015-11-10 | Sillajen Biotherapeutics, Inc. | Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses |
| US8980246B2 (en) | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
| US20070059833A1 (en) * | 2005-09-07 | 2007-03-15 | Maxcyte, Inc. | Use of Nucleases to Improve Viability and Enhance Transgene Expression in Transfected Cells |
| ATE546537T1 (en) | 2005-12-15 | 2012-03-15 | Targeted Growth Inc | INCREASED SEED SIZE AND SEED NUMBER DUE TO TRANSGENIC OVEREXPRESSION OF A GROWTH AND/OR DEVELOPMENT GENE DURING EARLY EMBYROD DEVELOPMENT |
| US7663020B2 (en) * | 2006-01-11 | 2010-02-16 | Agrinomics Llc | Generation of plants with altered oil content |
| EP2368570A3 (en) | 2006-01-18 | 2012-05-02 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
| US7868228B2 (en) | 2006-01-31 | 2011-01-11 | Monsanto Technology Llc | Phosphopantetheinyl transferases from bacteria |
| US7820883B2 (en) * | 2006-03-15 | 2010-10-26 | Dow Agrosciences Llc | Resistance to auxinic herbicides |
| DE602007010113D1 (en) | 2006-03-31 | 2010-12-09 | Reliance Life Sciences Pvt Ltd | Direct regeneration of young plants of the species Jathropha curcas |
| WO2008014484A1 (en) | 2006-07-27 | 2008-01-31 | University Of Maryland, Baltimore | Cellular receptor for antiproliferative factor |
| CA2921063C (en) | 2006-09-15 | 2020-01-28 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| EP2465510B1 (en) * | 2006-10-19 | 2018-11-28 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof |
| BRPI0717474A2 (en) | 2006-10-20 | 2014-03-11 | Arizona Board Of Regentes For And On Behalf Of Arizona State University | Modified cyanobacteria |
| WO2008061156A2 (en) | 2006-11-15 | 2008-05-22 | Agrigenetics, Inc. | Generation of plants with altered protein, fiber, or oil content |
| WO2008079545A2 (en) * | 2006-11-15 | 2008-07-03 | Agrigenetics, Inc. | Generation of plants with altered protein, fiber, or oil content |
| US8034993B2 (en) * | 2006-11-15 | 2011-10-11 | Dow Agrosciences Llc | Generation of plants with altered protein, fiber, or oil content |
| CA2669676C (en) * | 2006-11-15 | 2018-01-23 | Agrigenetics, Inc. | Generation of plants with altered protein, fiber, or oil content |
| US8106253B2 (en) * | 2006-11-15 | 2012-01-31 | Agrigenetics, Inc. | Generation of plants with altered protein, fiber, or oil content |
| WO2008067547A2 (en) | 2006-11-30 | 2008-06-05 | Research Development Foundation | Improved immunoglobulin libraries |
| EP2115150A4 (en) * | 2006-12-15 | 2010-06-02 | Agrinomics Llc | Generation of plants with altered oil, protein, or fiber content |
| US7563943B2 (en) * | 2006-12-15 | 2009-07-21 | Agrinomics Llc | Generation of plants with altered oil, protein, or fiber content |
| WO2008076831A2 (en) * | 2006-12-15 | 2008-06-26 | Agrinomics Llc | Generation of plants with altered oil, protein, or fiber content |
| US7790954B2 (en) * | 2006-12-15 | 2010-09-07 | Agrigenetics, Inc. | Generation of plants with altered oil, protein, or fiber content |
| MX2009006465A (en) * | 2006-12-15 | 2009-08-21 | Agrinomics Llc | Generation of plants with altered oil, protein, or fiber content. |
| KR20080084528A (en) | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | Oncolytic Vaccinia Virus Cancer Treatment |
| CA2685675C (en) | 2007-05-01 | 2016-02-16 | Research Development Foundation | Immunoglobulin fc libraries |
| BRPI0813098A2 (en) * | 2007-06-18 | 2014-11-11 | Agrinomics Llc | GENERATION OF PLANTS WITH CHANGED OIL, PROTEIN OR FIBER |
| AU2008292897B2 (en) | 2007-08-31 | 2015-01-22 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| CA2711499C (en) | 2008-01-10 | 2018-09-25 | Research Development Foundation | Vaccines and diagnostics for the ehrlichioses |
| US9746471B2 (en) | 2008-01-25 | 2017-08-29 | Multivir Inc. | P53 biomarkers |
| KR101648019B1 (en) | 2008-06-04 | 2016-08-16 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | Methods for the production of iPS cells using non-viral approach |
| WO2010019569A1 (en) | 2008-08-12 | 2010-02-18 | Cellular Dynamics International. Inc. | Methods for the production of ips cells |
| CA2734325A1 (en) | 2008-08-18 | 2010-02-25 | University Of Maryland, Baltimore | Derivatives of apf and methods of use |
| US20100203067A1 (en) | 2008-09-22 | 2010-08-12 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters |
| US20110262477A1 (en) | 2008-10-06 | 2011-10-27 | University Of Chicago | Compositions and Methods Related to Bacterial EAP, EMP, and/or ADSA Proteins |
| CA2737595C (en) | 2008-10-14 | 2017-09-12 | Monsanto Technology Llc | Utilization of fatty acid desaturases from hemiselmis spp. |
| JP5651125B2 (en) | 2008-12-10 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | MEK mutations that confer resistance to MEK inhibitors |
| WO2010084488A1 (en) | 2009-01-20 | 2010-07-29 | Ramot At Tel-Aviv University Ltd. | Mir-21 promoter driven targeted cancer therapy |
| WO2010096510A2 (en) | 2009-02-17 | 2010-08-26 | Edenspace Systems Corporation | Tempering of cellulosic biomass |
| HRP20160274T1 (en) | 2009-04-03 | 2016-04-08 | University Of Chicago | PREPARATIONS AND METHODS RELATED TO PROTEIN A (SPA) VARIATIONS |
| EP2424885B1 (en) | 2009-04-28 | 2016-03-23 | Vanderbilt University | Compositions and methods for the treatment of disorders involving epithelial cell apoptosis |
| WO2010138971A1 (en) | 2009-05-29 | 2010-12-02 | Edenspace Systems Corporation | Plant gene regulatory elements |
| CA2764373C (en) | 2009-06-05 | 2019-11-19 | FUJIFILM Cellular Dynamics, Inc. | Reprogramming t cells and hematophietic cells |
| CA2772298A1 (en) | 2009-08-26 | 2011-03-03 | Research Development Foundation | Methods for creating antibody libraries |
| WO2011032180A1 (en) | 2009-09-14 | 2011-03-17 | Jennerex, Inc. | Oncolytic vaccinia virus combination cancer therapy |
| WO2011050271A1 (en) | 2009-10-23 | 2011-04-28 | Monsanto Technology Llc | Methods and compositions for expression of transgenes in plants |
| BR112012013664B1 (en) | 2009-12-10 | 2020-11-10 | Turnstone Limited Partnership | oncolitic rhabdovirus |
| US10080799B2 (en) | 2010-02-12 | 2018-09-25 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions related to glycoprotein-immunoglobulin fusions |
| RU2571930C2 (en) | 2010-02-25 | 2015-12-27 | Дана-Фарбер Кэнсер Инститьют, Инк. | Braf mutations ensuing resistance to braf inhibitors |
| EP3214174B1 (en) | 2010-03-04 | 2019-10-16 | InteRNA Technologies B.V. | A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt |
| US8808699B2 (en) | 2010-04-05 | 2014-08-19 | The University Of Chicago | Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response |
| US9249195B2 (en) | 2010-04-07 | 2016-02-02 | Vanderbilt University | Reovirus vaccines and methods of use therefor |
| EP2560672B1 (en) | 2010-04-19 | 2014-03-05 | Research Development Foundation | Rtef-1 variants and uses thereof |
| US20110289625A1 (en) | 2010-05-19 | 2011-11-24 | Rujin Chen | Altered leaf morphology and enhanced agronomic properties in plants |
| WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
| EP3889254B8 (en) | 2010-06-09 | 2024-10-02 | Dana-Farber Cancer Institute, Inc. | A mek1 mutation conferring resistance to raf and mek inhibitors |
| ES2670842T5 (en) | 2010-06-15 | 2024-12-16 | Fujifilm Cellular Dynamics Inc | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
| WO2011159797A2 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | A compendium of ready-built stem cell models for interrogation of biological response |
| EP2588120B1 (en) | 2010-07-02 | 2017-11-15 | The University of Chicago | Compositions and methods related to protein a (spa) variants |
| EP3369817A1 (en) | 2010-07-06 | 2018-09-05 | InteRNA Technologies B.V. | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma , or in diseases or conditions with activated braf pathway |
| WO2012006440A2 (en) | 2010-07-07 | 2012-01-12 | Cellular Dynamics International, Inc. | Endothelial cell production by programming |
| WO2012018933A2 (en) | 2010-08-04 | 2012-02-09 | Cellular Dynamics International, Inc. | Reprogramming immortalized b cells |
| US9095540B2 (en) | 2010-09-09 | 2015-08-04 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens |
| EP2618829B1 (en) | 2010-09-22 | 2019-05-01 | The Regents of the University of Colorado, a body corporate | Smad7 for use in the treatment of oral mucositis or psoriasis |
| WO2012061615A1 (en) | 2010-11-03 | 2012-05-10 | The Samuel Roberts Noble Foundation, Inc. | Transcription factors for modification of lignin content in plants |
| US9919047B2 (en) | 2011-01-04 | 2018-03-20 | Sillajen, Inc. | Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus |
| EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
| CA2826467C (en) | 2011-02-07 | 2019-11-12 | Research Development Foundation | Engineered immunoglobulin fc polypeptides |
| WO2012109208A2 (en) | 2011-02-08 | 2012-08-16 | Cellular Dynamics International, Inc. | Hematopoietic precursor cell production by programming |
| EP2694534B1 (en) | 2011-04-08 | 2018-06-20 | Evaxion Biotech ApS | Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus |
| US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
| US8901371B2 (en) | 2011-05-06 | 2014-12-02 | The Samuel Roberts Noble Foundation, Inc. | Compositions and methods for improved plant feedstock |
| WO2012170304A2 (en) | 2011-06-02 | 2012-12-13 | The Regents Of The University Of California | Plants with elevated levels of glucan |
| CA2872045A1 (en) | 2011-06-08 | 2012-12-13 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Compositions and methods for glioblastoma treatment |
| CA2841165A1 (en) | 2011-07-11 | 2013-01-17 | Cellular Dynamics International, Inc. | Methods for cell reprogramming and genome engineering |
| WO2013025834A2 (en) | 2011-08-15 | 2013-02-21 | The University Of Chicago | Compositions and methods related to antibodies to staphylococcal protein a |
| US20130101664A1 (en) | 2011-08-18 | 2013-04-25 | Donald W. Kufe | Muc1 ligand traps for use in treating cancers |
| WO2013053899A1 (en) | 2011-10-12 | 2013-04-18 | Moeller Niels Iversen | Peptides derived from campylobacter jejuni and their use in vaccination |
| ES2886147T3 (en) | 2011-12-22 | 2021-12-16 | Interna Tech B V | MiRNAs for the treatment of head and neck cancer |
| JP6251730B2 (en) | 2012-04-26 | 2017-12-20 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | Compositions and methods related to antibodies that neutralize coagulase activity during STAPHYLOCOCUSAUREUS disease |
| HRP20201127T1 (en) | 2012-04-26 | 2020-11-27 | University Of Chicago | STAPHYLOCOCCAL COAGULASE ANTIGENS AND METHODS OF APPLICATION |
| MX360824B (en) | 2012-07-31 | 2018-11-15 | Univ Texas | Methods and compositions for in vivo induction of pancreatic beta cell formation. |
| FI3622810T3 (en) | 2012-09-24 | 2024-03-21 | Seminis Vegetable Seeds Inc | METHODS AND COMPOSITIONS FOR EXTENDING THE SHELF LIFE OF PLANT PRODUCTS |
| US9890216B2 (en) | 2012-10-23 | 2018-02-13 | Board Of Regents, The University Of Texas System | Antibodies with engineered IgG Fc domains |
| EP3800256A1 (en) | 2012-11-06 | 2021-04-07 | InteRNA Technologies B.V. | Combination to be used in therapeutic use against diseases or conditions associated with melanoma, or in diseases or conditions associated with activated b-raf pathway |
| WO2014116721A1 (en) | 2013-01-22 | 2014-07-31 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Geminiviral vector for expression of rituximab |
| RU2684211C2 (en) | 2013-02-21 | 2019-04-04 | Тёрнстоун Лимитед Партнершип | Vaccine composition |
| WO2014130770A1 (en) | 2013-02-22 | 2014-08-28 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
| EP2961386B1 (en) | 2013-02-28 | 2019-07-10 | The General Hospital Corporation | Mirna profiling compositions and methods of use |
| WO2014132137A2 (en) | 2013-03-01 | 2014-09-04 | Université De Genève | Transgenic cell selection |
| JP6576251B2 (en) | 2013-03-08 | 2019-09-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate | PTD-Smad7 drug therapy |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| US9944690B2 (en) | 2013-03-14 | 2018-04-17 | Bellicum Pharmaceuticals, Inc. | Methods for controlling T cell proliferation |
| EP3004329B1 (en) | 2013-06-05 | 2020-03-04 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| US11819555B2 (en) | 2013-09-09 | 2023-11-21 | Figene, Llc | Gene therapy for the regeneration of chondrocytes or cartilage type cells |
| CA2929555A1 (en) | 2013-11-08 | 2015-05-14 | Baylor Research Institute | Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure |
| WO2015070009A2 (en) | 2013-11-08 | 2015-05-14 | The Board Of Regents Of The University Of Texas System | Vh4 antibodies against gray matter neuron and astrocyte |
| ES3012932T3 (en) | 2013-12-03 | 2025-04-10 | Evaxion Biotech As | Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus |
| EP3099719B1 (en) | 2014-01-29 | 2020-04-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) |
| WO2015123561A2 (en) | 2014-02-14 | 2015-08-20 | University Of Utah Research Foundation | Methods and compositions for inhibiting retinopathy of prematurity |
| CA2937750A1 (en) | 2014-02-14 | 2015-08-20 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
| US20170037091A1 (en) | 2014-02-25 | 2017-02-09 | Research Development Foundation | Sty peptides for inhibition of angiogenesis |
| WO2015164228A1 (en) | 2014-04-21 | 2015-10-29 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
| AR100874A1 (en) | 2014-06-16 | 2016-11-09 | Consejo Nac De Investig Científicas Y Técnicas (Conicet) | CHEMICAL GENES AND PROTEINS OF OXIDATIVE RESISTANCE, AND TRANSGENIC PLANTS THAT INCLUDE THE SAME |
| EP3189148A4 (en) | 2014-09-02 | 2018-05-02 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides |
| ES2904301T3 (en) | 2014-11-03 | 2022-04-04 | Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum | Anti-Bob1 T cell receptors and uses thereof |
| CA2974716A1 (en) | 2014-11-12 | 2016-05-19 | Nmc, Inc. | Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same |
| WO2016075305A2 (en) | 2014-11-13 | 2016-05-19 | Evaxion Biotech Aps | Peptides derived from acinetobacter baumannii and their use in vaccination |
| ES2743232T3 (en) | 2014-12-15 | 2020-02-18 | Bellicum Pharmaceuticals Inc | Methods for the activation or controlled elimination of therapeutic cells |
| EP3244918A2 (en) | 2015-01-12 | 2017-11-22 | Evaxion Biotech ApS | Proteins and nucleic acids useful in vaccines targeting klebsiella pneumoniae |
| EP3250675A1 (en) | 2015-01-28 | 2017-12-06 | SABIC Global Technologies B.V. | Methods and compositions for high-efficiency production of biofuel and/or biomass |
| US10457737B2 (en) | 2015-02-09 | 2019-10-29 | Research Development Foundation | Engineered immunoglobulin Fc polypeptides displaying improved complement activation |
| US11421229B2 (en) | 2015-02-20 | 2022-08-23 | Baylor College Of Medicine | p63 inactivation for the treatment of heart failure |
| EP4219544A1 (en) | 2015-03-10 | 2023-08-02 | Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum | T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof |
| US20180201656A1 (en) | 2015-07-04 | 2018-07-19 | Evaxion Biotech Aps | Proteins and nucleic acids useful in vaccines targeting Pseudomonas Aeruginosa |
| US10526408B2 (en) | 2015-08-28 | 2020-01-07 | Research Development Foundation | Engineered antibody FC variants |
| AU2016342179B2 (en) | 2015-10-20 | 2022-08-18 | FUJIFILM Cellular Dynamics, Inc. | Multi-lineage hematopoietic precursor cell production by genetic programming |
| JP6983771B2 (en) | 2015-10-30 | 2021-12-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | A method for producing T cells from stem cells and an immunotherapeutic method using the T cells. |
| WO2017079202A1 (en) | 2015-11-02 | 2017-05-11 | Board Of Regents, The University Of Texas System | Methods of cd40 activation and immune checkpoint blockade |
| AU2016349632A1 (en) | 2015-11-07 | 2018-05-24 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| EP3373968B1 (en) | 2015-11-09 | 2024-04-17 | The Children's Hospital of Philadelphia | Glypican 2 as a cancer marker and therapeutic target |
| WO2017144523A1 (en) | 2016-02-22 | 2017-08-31 | Evaxion Biotech Aps | Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus |
| WO2017168348A1 (en) | 2016-03-31 | 2017-10-05 | Baylor Research Institute | Angiopoietin-like protein 8 (angptl8) |
| WO2017216384A1 (en) | 2016-06-17 | 2017-12-21 | Evaxion Biotech Aps | Vaccination targeting ichthyophthirius multifiliis |
| WO2017220787A1 (en) | 2016-06-24 | 2017-12-28 | Evaxion Biotech Aps | Vaccines against aearomonas salmonicida infection |
| CA3029582A1 (en) | 2016-07-01 | 2018-01-04 | Research Development Foundation | Elimination of proliferating cells from stem cell-derived grafts |
| US11414464B2 (en) | 2016-07-22 | 2022-08-16 | Evaxion Biotech A/S | Chimeric proteins for inducing immunity towards infection with S. aureus |
| US9963498B2 (en) | 2016-08-18 | 2018-05-08 | Wisconsin Alumni Research Foundation | Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R |
| US11147221B2 (en) | 2016-08-22 | 2021-10-19 | Biolumic Limited | Methods of seed treatment and resulting products |
| US11701384B2 (en) | 2016-09-02 | 2023-07-18 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
| CN110050061A (en) | 2016-10-05 | 2019-07-23 | 富士胶片细胞动力公司 | The mature pedigree of generation is induced multi-potent stem cell from what is destroyed with MeCP2 |
| CN110023491B (en) | 2016-10-05 | 2024-03-08 | 富士胶片细胞动力公司 | Methods for directed differentiation of pluripotent stem cells into HLA homozygous immune cells |
| RU2646108C1 (en) * | 2016-12-07 | 2018-03-01 | Федеральное государственное бюджетное учреждение науки Институт биологии развития им. Н.К. Кольцова РАН | Method for obtaining transgenic wheat plants using bioballistics |
| CA3046961A1 (en) | 2016-12-12 | 2018-06-21 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| EP3565576A1 (en) | 2017-01-05 | 2019-11-13 | Evaxion Biotech ApS | Vaccines targeting pseudomonas aeruginosa |
| US11371056B2 (en) | 2017-03-07 | 2022-06-28 | BASF Agricultural Solutions Seed US LLC | HPPD variants and methods of use |
| CA3055389A1 (en) | 2017-03-07 | 2018-09-13 | BASF Agricultural Solutions Seed US LLC | Hppd variants and methods of use |
| IL269716B2 (en) | 2017-04-18 | 2025-07-01 | Fujifilm Cellular Dynamics Inc | Activated cells specific antibody immunity |
| US20210147507A1 (en) | 2017-05-09 | 2021-05-20 | Bellicum Pharmaceuticals, Inc. | Methods to augment or alter signal transduction |
| US20220185849A1 (en) | 2017-05-19 | 2022-06-16 | Second Genome, Inc. | Proteins for the treatment of epithelial barrier function disorders |
| AU2018293468A1 (en) | 2017-06-29 | 2020-01-30 | Biolumic Limited | Method to improve crop yield and/or quality |
| WO2019038594A2 (en) | 2017-08-21 | 2019-02-28 | Biolumic Limited | High growth and high hardiness transgenic plants |
| US11634725B2 (en) | 2017-11-03 | 2023-04-25 | University Of Florida Research Foundation, Inc. | Methods and compositions for plant pathogen resistance in plants |
| AU2018358016A1 (en) | 2017-11-03 | 2020-05-07 | Interna Technologies B.V. | MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
| US11612618B2 (en) | 2017-11-14 | 2023-03-28 | Henry Ford Health System | Compositions for use in the treatment and prevention of cardiovascular disorders resulting from cerebrovascular injury |
| EP4137578A1 (en) | 2018-01-05 | 2023-02-22 | Ottawa Hospital Research Institute | Modified vaccinia vectors |
| WO2019145399A1 (en) | 2018-01-24 | 2019-08-01 | Evaxion Biotech Aps | Vaccines for prophylaxis of s. aureus infections |
| US12454561B2 (en) | 2018-03-19 | 2025-10-28 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| EP3775214A2 (en) | 2018-03-30 | 2021-02-17 | University of Geneva | Micro rna expression constructs and uses thereof |
| WO2020069313A2 (en) | 2018-09-28 | 2020-04-02 | Henry Ford Health System | Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke |
| WO2020083904A1 (en) | 2018-10-22 | 2020-04-30 | Evaxion Biotech Aps | Vaccines targeting m. catharrhalis |
| WO2020171889A1 (en) | 2019-02-19 | 2020-08-27 | University Of Rochester | Blocking lipid accumulation or inflammation in thyroid eye disease |
| EP3931206A1 (en) | 2019-02-27 | 2022-01-05 | Evaxion Biotech ApS | Vaccines targeting h. influenzae |
| US20210069242A1 (en) | 2019-04-18 | 2021-03-11 | Dmitry Dmitrievich Genkin | Reprogramming of polymorphonuclear leukocytes |
| CA3139981A1 (en) | 2019-05-14 | 2020-11-19 | The University Of Chicago | Methods and compositions comprising staphylococcus protein a (spa) variants |
| CN114555807B (en) | 2019-07-19 | 2025-05-16 | 费城儿童医院 | Chimeric antigen receptor containing a glypican 2 binding domain |
| US20210147525A1 (en) | 2019-10-18 | 2021-05-20 | The Regents Of The University Of California | Methods and compositions for treating pathogenic blood vessel disorders |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| WO2021140123A1 (en) | 2020-01-06 | 2021-07-15 | Evaxion Biotech Aps | Vaccines targeting neisseria gonorrhoeae |
| BR112022024027A2 (en) | 2020-05-27 | 2023-02-07 | Antion Biosciences Sa | ADAPTER MOLECULES TO REDIRECT CAR T CELLS TO AN ANTIGEN OF INTEREST |
| KR20230019453A (en) | 2020-05-29 | 2023-02-08 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | Double cell aggregates of retinal pigment epithelial cells and photoreceptors and methods of use thereof |
| MX2022015002A (en) | 2020-05-29 | 2023-03-03 | Fujifilm Cellular Dynamics Inc | B-LAYER OF THE RETINAL PIGMENTAL EPITHELIUM AND PHOTORECEPTORS AND THEIR USE. |
| WO2022053130A1 (en) | 2020-09-09 | 2022-03-17 | Sid Alex Group, S.R.O. | Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers |
| EP4570256A3 (en) | 2020-11-05 | 2025-09-24 | Board of Regents, The University of Texas System | Engineered t cell receptors targeting egfr antigens and methods of use |
| AU2021401052A1 (en) | 2020-12-18 | 2023-06-22 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CA3202849A1 (en) | 2021-02-09 | 2022-08-18 | University Of Houston System | Oncolytic virus for systemic delivery and enhanced anti-tumor activities |
| US20240122865A1 (en) | 2021-02-19 | 2024-04-18 | Pfizer Inc. | Methods of Protecting RNA |
| BR112023020861A2 (en) | 2021-04-08 | 2023-12-12 | Janssen Biotech Inc | MATERIALS AND METHODS FOR OPTIMIZED GENETIC MODIFICATION OF MEMORY T CELLS ANALOGOUS TO STEM CELLS |
| US20240368541A1 (en) | 2021-05-03 | 2024-11-07 | Astellas Institute For Regenerative Medicine | Methods of generating mature corneal endothelial cells |
| CN117716020A (en) | 2021-05-07 | 2024-03-15 | 安斯泰来再生医药协会 | Method for producing mature hepatocytes |
| WO2022251443A1 (en) | 2021-05-26 | 2022-12-01 | FUJIFILM Cellular Dynamics, Inc. | Methods to prevent rapid silencing of genes in pluripotent stem cells |
| AU2022307747A1 (en) | 2021-07-05 | 2024-01-25 | Evaxion Biotech A/S | Vaccines targeting neisseria gonorrhoeae |
| WO2023081813A1 (en) | 2021-11-05 | 2023-05-11 | St. Jude Children's Research Hospital, Inc. | Zip cytokine receptors |
| US20250257388A2 (en) | 2021-11-08 | 2025-08-14 | St. Jude Children's Research Hospital, Inc. | Pre-effector car-t cell gene signatures |
| EP4436595A1 (en) | 2021-11-22 | 2024-10-02 | Pfizer Inc. | Reducing risk of antigen mimicry in immunogenic medicaments |
| GB2614309A (en) | 2021-12-24 | 2023-07-05 | Stratosvir Ltd | Improved vaccinia virus vectors |
| US20250177514A1 (en) | 2022-01-28 | 2025-06-05 | Pfizer Inc. | Coronavirus antigen variants |
| EP4493213A1 (en) | 2022-03-16 | 2025-01-22 | University of Houston System | Persistent hsv gene delivery system |
| GB202206507D0 (en) | 2022-05-04 | 2022-06-15 | Antion Biosciences Sa | Expression construct |
| US20250288657A1 (en) | 2022-05-04 | 2025-09-18 | Evaxion Biotech A/S | Staphylococcal protein variants and truncates |
| KR20250035053A (en) | 2022-06-07 | 2025-03-11 | 리제너론 파아마슈티컬스, 인크. | Multispecific molecules for modulating T cell activity and uses thereof |
| EP4536687A1 (en) | 2022-06-08 | 2025-04-16 | St. Jude Children's Research Hospital, Inc. | Disruption of kdm4a in t cells to enhance immunotherapy |
| JP2025519556A (en) | 2022-06-10 | 2025-06-26 | リサーチ ディベロップメント ファウンデーション | Engineered FcRIIb-selective IgG1 Fc variants and uses thereof |
| EP4547824A1 (en) | 2022-06-29 | 2025-05-07 | Fujifilm Holdings America Corporation | Ipsc-derived astrocytes and methods of use thereof |
| WO2024059787A1 (en) | 2022-09-16 | 2024-03-21 | St. Jude Children's Research Hospital, Inc. | Disruption of asxl1 in t cells to enhance immunotherapy |
| WO2024130212A1 (en) | 2022-12-16 | 2024-06-20 | Turnstone Biologics Corp. | Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors |
| WO2024186630A1 (en) | 2023-03-03 | 2024-09-12 | Henry Ford Health System | Use of extracellular vesicles for the treatment of cancer |
| GB202306619D0 (en) | 2023-05-04 | 2023-06-21 | Antion Biosciences Sa | Cell |
| WO2025050009A2 (en) | 2023-09-01 | 2025-03-06 | Children's Hospital Medical Center | Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens |
| GB202402745D0 (en) | 2024-02-27 | 2024-04-10 | Antion Biosciences Sa | Cell |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4801545A (en) * | 1983-05-19 | 1989-01-31 | Plant Genetics, Inc. | Enhanced somatic embryogenesis using maltose |
| US5036006A (en) * | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| GB8611818D0 (en) * | 1986-05-15 | 1986-06-25 | Shell Int Research | Plant generation method |
| FI890917L (en) * | 1988-03-02 | 1989-09-03 | Eidgenoess Tech Hochschule | FOERFARANDE FOER FRAMSTAELLNING AV TRANSGENA VAEXTER. |
| EP0397413B1 (en) * | 1989-05-12 | 1994-01-12 | Pioneer Hi-Bred International, Inc. | Improved particle gun |
| EP0814166A3 (en) * | 1989-08-09 | 1998-05-13 | DeKalb Genetics Corporation | Methods and compositions for the production of stably transformed fertile monocot plants and cells thereof |
| EP0442174A1 (en) * | 1990-02-13 | 1991-08-21 | Pioneer Hi-Bred International, Inc. | Stable transformation of plant cells |
| JP3234598B2 (en) * | 1990-11-23 | 2001-12-04 | プラント・ジエネテイツク・システムズ・エヌ・ベー | Transformation method of monocotyledonous plant |
| WO1993004178A1 (en) * | 1991-08-23 | 1993-03-04 | University Of Florida | A novel method for the production of transgenic plants |
| AU2781892A (en) * | 1991-10-07 | 1993-05-03 | Ciba-Geigy Ag | Particle gun for introducing dna into intact cells |
| US5610042A (en) * | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
| IL101119A0 (en) * | 1992-03-03 | 1992-11-15 | Univ Ramot | Transgenic wheat |
-
1993
- 1993-11-01 US US08/147,261 patent/US5610042A/en not_active Expired - Lifetime
- 1993-12-13 DK DK94903608T patent/DK0674715T4/en active
- 1993-12-13 AU AU57493/94A patent/AU688297B2/en not_active Expired
- 1993-12-13 CA CA002151127A patent/CA2151127C/en not_active Expired - Lifetime
- 1993-12-13 AT AT94903608T patent/ATE181364T1/en not_active IP Right Cessation
- 1993-12-13 ES ES94903608T patent/ES2134925T5/en not_active Expired - Lifetime
- 1993-12-13 EP EP94903608A patent/EP0674715B2/en not_active Expired - Lifetime
- 1993-12-13 DE DE69325389T patent/DE69325389T3/en not_active Expired - Lifetime
- 1993-12-13 WO PCT/US1993/012085 patent/WO1994013822A2/en not_active Ceased
-
1997
- 1997-03-06 US US08/812,215 patent/US5955362A/en not_active Expired - Lifetime
-
1999
- 1999-08-23 GR GR990402132T patent/GR3031054T3/en unknown
Cited By (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521241B2 (en) | 1994-08-20 | 2009-04-21 | Gendaq Limited | Regulated gene expression in plants |
| US5631152A (en) * | 1994-10-26 | 1997-05-20 | Monsanto Company | Rapid and efficient regeneration of transgenic plants |
| EP0709462A3 (en) * | 1994-10-26 | 1997-01-02 | Monsanto Co | Fast and efficient regeneration of transgenic plants |
| US6153812A (en) * | 1994-10-26 | 2000-11-28 | Monsanto Company | Rapid and efficient regeneration of transgenic wheat plants |
| US7026528B2 (en) | 1996-06-21 | 2006-04-11 | Monsanto Technology Llc | Methods for the production of stably-transformed, fertile wheat employing agrobacterium-mediated transformation and compositions derived therefrom |
| WO1998004723A1 (en) * | 1996-07-26 | 1998-02-05 | Regents Of The University Of Minnesota | Fertile transgenic oat plants |
| US5773269A (en) * | 1996-07-26 | 1998-06-30 | Regents Of The University Of Minnesota | Fertile transgenic oat plants |
| US6002068A (en) * | 1996-12-19 | 1999-12-14 | Novartis Finance Corporation | Methods for conferring insect resistance to a monocot using a perioxidase coding sequence |
| US6235529B1 (en) | 1997-04-29 | 2001-05-22 | The Regents Of The University Of California | Compositions and methods for plant transformation and regeneration |
| US6541257B2 (en) | 1997-04-29 | 2003-04-01 | The Regents Of The University Of California | Method for preparing barley green regenerative tissue |
| US7102056B1 (en) | 1997-04-29 | 2006-09-05 | The Regents Of The University Of California | Compositions and methods for plant transformation and regeneration |
| WO1998048613A1 (en) * | 1997-04-29 | 1998-11-05 | The Regents Of The University Of California | Compositions and methods for plant transformation and regeneration |
| US6486384B1 (en) | 1997-09-24 | 2002-11-26 | The Regents Of The University Of California | Methods and compositions for transformation of cereals using cultured shoot meristematic tissue |
| WO1999015003A1 (en) * | 1997-09-24 | 1999-04-01 | The Regents Of The University Of California | Methods and compositions for transformation of cereals using cultured shoot meristematic tissue |
| US6642437B1 (en) | 1997-09-30 | 2003-11-04 | The Regents Of The University Of California | Production of proteins in plant seeds |
| EP2258856A1 (en) | 1998-02-20 | 2010-12-08 | Syngenta Limited | Hybrid seed production |
| US7262055B2 (en) | 1998-08-25 | 2007-08-28 | Gendaq Limited | Regulated gene expression in plants |
| US7285416B2 (en) | 2000-01-24 | 2007-10-23 | Gendaq Limited | Regulated gene expression in plants |
| EP2078455A1 (en) | 2001-03-06 | 2009-07-15 | The Dow Chemical Company | Plant cell having animal-type sugar chain adding function |
| US7667099B2 (en) | 2002-06-20 | 2010-02-23 | Board Of Trustees Of Michigan State University | Plastid division and related genes and proteins, and methods of use |
| EP2390333A1 (en) | 2002-07-23 | 2011-11-30 | Novozymes Biopharma DK A/S | Polypeptides comprising a modified human serum albumin secretion pre-sequence with improved secretion yield |
| US7429691B2 (en) | 2002-09-03 | 2008-09-30 | The Regents Of The University Of California | Methods and compositions for transformation and regeneration of maize |
| US8674176B2 (en) | 2003-05-29 | 2014-03-18 | Ingo H. Heilmann | ADS genes for reducing saturated fatty acid levels in seed oils |
| EP2290084A2 (en) | 2003-06-30 | 2011-03-02 | Commonwealth Scientific and Industrial Research Organization | Wheat with altered branching enzyme activity and starch and starch containing products derived therefrom |
| WO2005123926A1 (en) | 2004-06-18 | 2005-12-29 | Thomas Schmulling | Method for modifying plant morphology, biochemistry and physiology comprising expression of cytokinin oxydase in the seeds |
| US7834244B2 (en) | 2004-12-21 | 2010-11-16 | Huazhong Agricultural University | Transcription factor gene OsNACx from rice and use thereof for improving plant tolerance to drought and salt |
| US8378173B2 (en) | 2004-12-21 | 2013-02-19 | Huazhong Agricultural University | Transcription factor gene OsNACx from rice and use thereof for improving plant tolerance to drought and salt |
| US7781648B2 (en) | 2005-05-18 | 2010-08-24 | Board Of Trustees Of Michigan State University | Resistance to soybean aphid in early maturing soybean germplasm |
| EP2666867A1 (en) | 2006-07-12 | 2013-11-27 | The Board Of Trustees Operating Michigan State University | DNA encoding ring zinc-finger protein and the use of the DNA in vectors and bacteria and in plants |
| US9187761B2 (en) | 2006-09-25 | 2015-11-17 | Thomas Schmulling | Transcriptional repressors of cytokinin signaling and their use |
| US9133475B2 (en) | 2008-11-26 | 2015-09-15 | Board Of Trustees Of Michigan State University | Aphid resistant soybean plants |
| US9062331B2 (en) | 2008-12-18 | 2015-06-23 | Board Of Trustees Of Michigan State University | Enzyme directed oil biosynthesis in microalgae |
| US8362318B2 (en) | 2008-12-18 | 2013-01-29 | Board Of Trustees Of Michigan State University | Enzyme directed oil biosynthesis in microalgae |
| US9771605B2 (en) | 2008-12-18 | 2017-09-26 | Board Of Trustees Of Michigan State University | Enzyme directed oil biosynthesis in microalgae |
| US9328335B2 (en) | 2009-12-30 | 2016-05-03 | Board Of Trustees Of Michigan State University | Method to produce acetyldiacylglycerols (ac-TAGs) by expression of an acetyltransferase gene isolated from Euonymus alatus (burning bush) |
| WO2013005211A2 (en) | 2011-07-05 | 2013-01-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Boron complexing plant materials and uses thereof cross-reference to related applications |
| US10253329B2 (en) | 2013-01-04 | 2019-04-09 | Board Of Trustees Of Michigan State University | Sources of aphid resistance in soybean plants |
| US10392629B2 (en) | 2014-01-17 | 2019-08-27 | Board Of Trustees Of Michigan State University | Increased caloric and nutritional content of plant biomass |
| US9307708B2 (en) | 2014-03-07 | 2016-04-12 | Pioneer Hi-Bred International Inc | Systems for extracting monocot embryos |
| US9320210B2 (en) | 2014-03-07 | 2016-04-26 | Pioneer Hi Bred Internatonal Inc | Methods of extracting monocot embryos |
| WO2016039961A1 (en) | 2014-09-11 | 2016-03-17 | Marrone Bio Innovations, Inc | Chromobacterium subtsugae genome |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2134925T5 (en) | 2007-06-01 |
| ES2134925T3 (en) | 1999-10-16 |
| AU688297B2 (en) | 1998-03-12 |
| DE69325389T3 (en) | 2007-02-08 |
| DE69325389D1 (en) | 1999-07-22 |
| EP0674715B2 (en) | 2006-10-11 |
| WO1994013822A3 (en) | 1994-09-15 |
| DK0674715T3 (en) | 1999-11-29 |
| DE69325389T2 (en) | 1999-11-25 |
| CA2151127A1 (en) | 1994-06-23 |
| EP0674715A1 (en) | 1995-10-04 |
| GR3031054T3 (en) | 1999-12-31 |
| DK0674715T4 (en) | 2007-02-19 |
| US5955362A (en) | 1999-09-21 |
| EP0674715B1 (en) | 1999-06-16 |
| CA2151127C (en) | 2008-03-25 |
| ATE181364T1 (en) | 1999-07-15 |
| AU5749394A (en) | 1994-07-04 |
| US5610042A (en) | 1997-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU688297B2 (en) | Methods for stable transformation of wheat | |
| US5969213A (en) | Methods and compositions for the production of stably transformed fertile monocot plants and cells thereof | |
| EP0442174A1 (en) | Stable transformation of plant cells | |
| WO1991002071A2 (en) | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof | |
| CA2321781C (en) | Particle bombardment transformation of brassica | |
| US20240093222A1 (en) | Methods for transforming corn explants | |
| US6140555A (en) | Methods for maize transformation coupled with adventitious regeneration utilizing nodal section explants and mature zygotic embryos | |
| US6486384B1 (en) | Methods and compositions for transformation of cereals using cultured shoot meristematic tissue | |
| Abedinia et al. | An efficient transformation system for the Australian rice cultivar, Jarrah | |
| US20100281565A1 (en) | Transformation of Crambe Abyssinica | |
| EP1745132A1 (en) | Methods for high efficiency transformation and regeneration of plant suspension cultures | |
| US7429691B2 (en) | Methods and compositions for transformation and regeneration of maize | |
| US6570068B1 (en) | Methods for maize transformation coupled with adventitious regeneration utilizing nodal section explants and mature zygotic embryos | |
| CA2064761C (en) | Methods and compositions for the production of stably transformed fertile monocot plants and cells thereof | |
| US20040210958A1 (en) | A Novel Culture Method for Corn Transformation | |
| Somers et al. | Genetic transformation in Avena sativa L.(oat) | |
| Eissa | Genetic Transformation via Biolistic Gene Gun Method and Regeneration of Common Bean | |
| Gulati et al. | In vitro regeneration and genetic transformation of lentil | |
| AU723435B2 (en) | Particle mediated transformation of cotton | |
| Oneto et al. | Maize Genetic Transformation: The Biolistic Protocol | |
| Simmonds | Gene transfer in the Gramineae. | |
| SOMERS¹ et al. | II. 3 Genetic Transformation in Avena sativa L.(Oat) | |
| CA2440416A1 (en) | Particle bombardment transformation of brassica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK LV MG MN MW NO NZ PL RO RU SD SK UA US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK LV MG MN MW NO NZ PL RO RU SD SK UA US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| EX32 | Extension under rule 32 effected after completion of technical preparation for international publication | ||
| LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1994903608 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2151127 Country of ref document: CA |
|
| WWP | Wipo information: published in national office |
Ref document number: 1994903608 Country of ref document: EP |
|
| WWG | Wipo information: grant in national office |
Ref document number: 1994903608 Country of ref document: EP |





